Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
The net profit margin is -173.85%.
Reported quarterly profit margin; no daily interpolation. Q4 FY2025 (2025-12-31): 0.00%.
NET PROFIT MARGIN
-173.85%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
N/A
NET PROFIT MARGIN AVG 5Y
N/A
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.35%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-49571.43%
vs the sector median at left
SL Science Holding Ltd
Market Cap
$852.35M
Net Profit Margin
-173.85%
TTM Avg
0.00%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$853.13M
Net Profit Margin
116.30%
TTM Avg
67.23%
3Y Avg
16.07%
5Y Avg
4.15%
Market Cap
$855.38M
Net Profit Margin
-5933.45%
TTM Avg
-505.88%
3Y Avg
-252.94%
5Y Avg
-252.94%
Market Cap
$857.16M
Net Profit Margin
-39.20%
TTM Avg
-57.59%
3Y Avg
-24.68%
5Y Avg
-1.42%
Market Cap
$838.62M
Net Profit Margin
-82.49%
TTM Avg
-271.33%
3Y Avg
-235.13%
5Y Avg
-173.69%
Market Cap
$838.16M
Net Profit Margin
-61.32%
TTM Avg
-78.55%
3Y Avg
-9174.62%
5Y Avg
-9174.62%
Market Cap
$867.03M
Net Profit Margin
-6.85%
TTM Avg
-13.95%
3Y Avg
-29.17%
5Y Avg
-39.83%
Market Cap
$870.81M
Net Profit Margin
-4994.86%
TTM Avg
-4994.86%
3Y Avg
-4994.86%
5Y Avg
-4994.86%
Market Cap
$833.81M
Net Profit Margin
-560.85%
TTM Avg
-63.69%
3Y Avg
-31.84%
5Y Avg
-21.23%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SL Science Holding Ltd (SLBT) | $852.35M | -173.85% | 0.00% | N/A | N/A |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $853.13M | 116.30% | 67.23% | 16.07% | 4.15% |
| Alumis Inc. (ALMS)vs › | $855.38M | -5933.45% | -505.88% | -252.94% | -252.94% |
| QuidelOrtho Corporation (QDEL)vs › | $857.16M | -39.20% | -57.59% | -24.68% | -1.42% |
| Pacific Biosciences of California, Inc. (PACB)vs › | $838.62M | -82.49% | -271.33% | -235.13% | -173.69% |
| Beta Bionics, Inc. (BBNX)vs › | $838.16M | -61.32% | -78.55% | -9174.62% | -9174.62% |
| SI-BONE, Inc. (SIBN)vs › | $867.03M | -6.85% | -13.95% | -29.17% | -39.83% |
| Odyssey Therapeutics, Inc. (ODTX)vs › | $870.81M | -4994.86% | -4994.86% | -4994.86% | -4994.86% |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $833.81M | -560.85% | -63.69% | -31.84% | -21.23% |
| SpyGlass Pharma, Inc. Common Stock (SGP)vs › | $828.48M | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Margin
-174.7%
Net Profit Margin
-173.8%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2025-12-31 | 0.00% |
| 2025-06-30 | 0.00% |
| 2024-12-31 | 0.00% |
